Kyongbo Pharmaceutical Co., Ltd (KRX:214390)
South Korea flag South Korea · Delayed Price · Currency is KRW
5,190.00
+100.00 (1.96%)
Last updated: Aug 3, 2026, 1:36 PM KST

Kyongbo Pharmaceutical Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
269,642264,104238,556216,357196,265170,660
Revenue Growth
13.99%10.71%10.26%10.24%15.00%-20.73%
Gross Profit
105,684102,30489,27462,57643,86734,731
Operating Income
4,1103,51910,4545,5451,393-6,625
Net Income
347.4182.294,6392,974610.59-7,495
Earnings Per Share
14.547.63194.00124.4226.00-314.00
EPS Growth
-84.84%-96.07%55.93%378.52%--

Revenue by Segment

Fiscal YearFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec '24 Dec '23 Dec '22 Dec '21 Dec '20
Raw Material
138,268139,990144,076125,164167,154
Finished Products
100,28976,36852,18945,49548,131

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
9,9518,0486,1285,3477,2184,290
Total Debt
143,029126,67191,43375,93664,51256,587
Net Cash (Debt)
-133,078-118,623-85,305-70,589-57,294-52,296
Net Cash Growth
------
Net Cash Per Share
-5569.50-4961.88-3567.15-2952.68-2439.66-2190.88

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
11,2337,456149.124,84410,12717,968
Capital Expenditures
-50,956-41,538-12,697-9,693-12,874-17,506
Free Cash Flow
-39,723-34,083-12,547-4,849-2,747461.73
Free Cash Flow Growth
------94.72%

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
39.19%38.74%37.42%28.92%22.35%20.35%
Operating Margin
1.52%1.33%4.38%2.56%0.71%-3.88%
Pretax Margin
0.26%0.17%2.06%1.00%-0.31%-5.82%
Profit Margin
0.13%0.07%1.94%1.38%0.31%-4.39%
FCF Margin
-14.73%-12.90%-5.26%-2.24%-1.40%0.27%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
352.34756.7032.0567.44391.54-
P/FCF Ratio
-----556.60
PS Ratio
0.450.520.620.931.221.51